Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

News · April 06, 2022

AAD 2022: Apremilast May Aid Cardiometabolic Health in Patients With Psoriasis

New phase 4 data show apremilast tied to some improvement in cardiometabolic biomarkers and significant reductions in visceral, subcutaneous fat

PracticeUpdate Editorial Team


Further Reading